Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency 2Kidney Failure, Chronic 2Carcinoma, Renal Cell 2Virus Diseases 1Renal Insufficiency, Chronic 1Multiple Myeloma 1Hematologic Neoplasms 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 7Valganciclovir 5Valacyclovir 3Gemcitabine 3Dexamethasone 3Cisplatin 3spartalizumab 2pegaspargase 2Radiotherapy, Intensity-Modulated 2Methylprednisolone 2Lenalidomide 2Etoposide 2Doxorubicin 2Cell Count 2Blood Specimen Collection 2valomaciclovir 1toripalimab 1ruxolitinib 1pembrolizumab 1merphos 1fludarabine 1dehydroftorafur 1avelumab 1apatinib 1Zidovudine 1Watchful Waiting 1Valproic Acid 1Vaccines 1Tenofovir 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Epstein-Barr Virus Infections × Kidney Transplantation × Clear all
NCT01136395 2019-10-08

Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation

University of Giessen

Phase 2 Completed
85 enrolled

Virus Diseases, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡